Trial Profile
Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 14 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Sep 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 19 Sep 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.